Eli Lilly and Company shares closed at $1,124.10 on September 10, 2026, edging higher by 0.02% over the prior 24 hours. The marginal daily gain offered little relief from a broader stretch of selling pressure that has weighed on the pharmaceutical giant in recent weeks.
Over the past seven days, LLY has fallen 3.10%, while the 30-day decline stands at 8.73%. The cumulative losses over that one-month window represent a notable pullback for a stock that carries a market capitalization of $1,024.49 billion.
Despite the recent weakness, Eli Lilly remains one of the largest publicly traded companies by market value, reflecting its substantial footprint in the pharmaceutical sector. The 30-day slide has trimmed significant value in absolute dollar terms given the company's trillion-dollar market cap.
The modest 24-hour uptick suggests some stabilization at current price levels, though the longer-term trend over the past month continues to point lower. Market participants will be watching whether the stock can reclaim lost ground or faces continued headwinds in the sessions ahead.
